Inactive Instrument

Hemispherx BioPharma, Inc Share Price Nyse

Equities

US42366C3016

Biotechnology & Medical Research

Sales 2024 * - Sales 2025 * 2.57M 214M Capitalization 21.37M 1.78B
Net income 2024 * -27M -2.25B Net income 2025 * -28M -2.34B EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 8.31 x
P/E ratio 2024 *
-0.79 x
P/E ratio 2025 *
-0.91 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 91.01%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Hemispherx BioPharma, Inc

Managers TitleAgeSince
Chief Executive Officer 71 17/08/17
Director of Finance/CFO 68 04/22/04
Chief Tech/Sci/R&D Officer - 01/22/01
Members of the board TitleAgeSince
Director/Board Member 66 28/23/28
Chairman 89 01/98/01
Chief Executive Officer 71 17/08/17
More insiders
AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
More about the company